| EDAP Appoints Dr. John C. Rewcastle as International Medical Director
LYON, France, June 28 /PRNewswire-FirstCall/ -- EDAP TMS S.A. , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announces the appointment of Dr. John C. Rewcastle as International Medical Director. Dr Rewcastle's duties will include significant involvement in the company's accelerating US clinical trial as well as general education and research roles associated with the clinical program in North America. "The goal of all prostate cancer therapies is to effectively treat the disease but not impact the patient's quality of life," said Dr. Rewcastle. "I believe that HIFU has the ability to meet this goal for the majority of patients diagnosed with localized prostate cancer. Further, the Ablatherm-HIFU device is ideally suited for the North American market, and I foresee rapid adoption following FDA approval." Dr.
Substance In Tree Bark Could Lead To New Lung-Cancer Treatment
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
The compound, called beta-lapachone, has shown promising anti-cancer properties and is currently being used in a clinical trial to examine its effectiveness against pancreatic cancer in humans. Until now, however, researchers didn't know the mechanism of how the compound killed cancer cells.
Dr. David Boothman, a professor in the Harold C. Simmons Comprehensive Cancer Center and senior author of a study appearing online in the Proceedings of the National Academy of Sciences, has been researching the compound and how it causes cell death in cancerous cells for 15 years.
IntraOp Delivers Mobetron to Chinese Academy of Medical Sciences ...
IntraOp Medical Corporation (OTCBB: IOPM), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced it has delivered a Mobetron(R) system to the Cancer Institute & Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, China. Mobetron is a proprietary, mobile electron-beam instrument designed for Intraoperative Electron Radiation Therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The Mobetron will form an integral component in the Chinese Government's new initiative to combat lung cancer as well as be used to provide IOERT treatment for a variety of other cancers. Dr. Donald A. Goer, president and CEO of IntraOp Medical Corporation, said, "Lung cancer is a major worldwide health problem and one of China's fastest growing diseases.
|
